Recent developments to share with you

Yehui Medicine and Kangchuanji Hold "Trusted Partner" Plaque Presentation Ceremony

2023-09-11

Recently, Kangchuanji helped Yehui Medicine achieve implied approval for its BN104 Clinical Trial Application (IND) in China. On the morning of September 5, a delegation from Yehui Medicine led by CEO Hua Ye visited our company for an exchange and held a "Trusted Partner" plaque presentation ceremony. Attendees included Hua Ye (CEO of Yehui Medicine), Wang Peng (Senior Director of Pharmaceutical Sciences), Zhou Yongsheng (Senior Manager of Formulation), Gong Yujing (Manager of Analysis), as well as Yin Lifang (General Manager of Kangchuanji), and Deputy General Managers Zhu Chunli, Yang Debao, Chen Jintuo, and Hu Haijian.

BN104 is a novel, highly selective oral Menin inhibitor. Menin inhibitors are currently recognized by the academic community as a potential treatment for patients with acute leukemia carrying MLL rearrangements or NPM1 mutations. In preclinical studies comparing BN104 with other Menin inhibitors in clinical stages, BN104 has demonstrated better efficacy and a significantly wider safety margin, positioning it as a potential best-in-class candidate.

Yehui Medicine is a biopharmaceutical company focused on clinical development innovation. The company is committed to developing and commercializing innovative drugs to address unmet medical needs. Headquartered in Shanghai, Yehui Medicine is a rapidly growing startup. Its product pipeline is built on internal R&D, collaborations with cutting-edge biotech companies, and the introduction of high-quality overseas projects. With a strong and experienced team supported by capital, Yehui Medicine provides high-quality innovative drugs to patients in China and around the world.

Keywords：

Jiuzhou Pharmaceutical Included in the FTSE4Good Index Series for the First Time

School of Pharmacy, China Pharmaceutical University Holds Plaque Presentation Ceremony with Nanjing Kangchuanji for Graduate Employment Base

Related information

Bountiful Results | January–July 2026: Kangchuanji Pharmaceutical, in collaboration with multiple pharmaceutical companies, secured approval or passed the evaluation for 15 product specifications.

From January to July 2026, Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd., leveraging its deep-rooted pharmaceutical R&D expertise and mature end-to-end CDMO capabilities, has provided robust support for the innovative R&D and commercialization of its partner companies, achieving further regulatory‑review milestones in collaboration with multiple partners. According to the NMPA’s public announcement of drug approval documents, a total of 12 drug products (covering 15 specifications) have been successfully approved or passed consistency evaluation, demonstrating significant results in translating innovative research into tangible outcomes.

2026-08-04

CDE Announcement: Updated Guidelines for Pediatric Medicines! “Technical Guidance on the Application of Physiologically Based Pharmacokinetic Models in Drug Development for Pediatric Populations (Draft for Public Comment)”

On August 17, the CDE released a draft of the “Technical Guidance for the Application of Physiologically Based Pharmacokinetic Models in Pediatric Drug Development” for public comment.

2024-10-27

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

2026-07-03

Please contact us for more detailed information.

Kangchuanji Pharmatech looks forward to working with you and jointly creating a bright future!

Nanjing Kangchuanji Pharmatech Co., Ltd.

Contact Us：18020149597（HR）
Recruitment Email:recruit@kcjpharma.com
Address: 2nd Floor, Building 5, No.199 Wenfang Road, Jiangning District, Nanjing, Jiangsu Province, China（Jiangning High-tech Park）

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

南京康川济医药科技有限公司

Recent developments to share with you

Yehui Medicine and Kangchuanji Hold "Trusted Partner" Plaque Presentation Ceremony

COOKIES

COOKIES